The recent stock price drop in Hims & Hers Health (HIMS) presents a potential long-term buying opportunity for investors. Despite short-term market concerns, the company's fundamental growth in revenue and subscribers remains strong. Future growth is expected from the launch of a new longevity product line and expansion into Hormone Replacement Therapy (HRT). The company is also beginning its international expansion into Canada, starting with its weight loss offerings. These catalysts support a bullish long-term outlook, suggesting the core investment thesis is as strong as ever.

Hims & Hers Health, Inc. (HIMS)

• The stock experienced a significant drop (-13%, later recovering to -8%) immediately following its Q2 earnings announcement.
• The host views the long-term trajectory as "stunning" despite the market's negative short-term reaction.
• Strong Year-Over-Year Growth:
  • Revenue Growth: +73%
  • Net Income: +220%
  • Adjusted EBITDA (a proxy for cash flow): +109%
• Subscriber and Revenue Metrics:
  • The number of subscribers grew by 31%, reaching over 2 million members.
  • Revenue growth is increasingly driven by higher spending per user, not just new customer acquisition.
  • Monthly online revenue per average user increased by 30%.
• Business Strategy - The "Flywheel":
  • HIMS is heavily focused on personalization (customized pills and dosages).
  • The strategy is that personalized treatments lead to better patient outcomes, which improves customer retention and drives word-of-mouth growth, creating a positive feedback loop.
• Future Growth Catalysts:
  • International Expansion: The company is entering Canada, starting with its weight loss offerings, capitalizing on the end of a patent for semaglutide.
  • Longevity: This is highlighted as a major new potential market. The company may start offering products like metformin, spermidine, and resveratrol, which are popular in the longevity community. The host believes this could be "very big."
  • Hormone Replacement Therapy (HRT): HIMS plans to launch HRT services, including testosterone therapy for men, which is made possible by its previous acquisition of Tribe for at-home blood testing.
• Risks and Short-Term Concerns:
  • No Guidance Increase: Unlike in previous quarters, HIMS did not raise its future financial guidance. This could signal a potential slowdown.
  • Impact from Novo Nordisk: The host believes Q2 results were negatively impacted ("truncated") by Novo Nordisk's decision to stop partnering with telehealth companies for its GLP-1 weight loss drugs. This likely hurt HIMS's marketing efforts and sales towards the end of the quarter.
  • Quarterly Cash Flow Dip: Adjusted EBITDA and cash flow were down for the quarter, which the company attributes to investments in automation and innovation.
• Financial Health: The company maintains a strong balance sheet with approximately $1 billion in cash.

Takeaways

• The host's sentiment is very bullish for the long term, viewing the current stock price drop as a "blip" and a potential buying opportunity. The core investment thesis is considered "as strong as ever."
• Investors should look beyond the short-term noise of the Novo Nordisk issue and focus on the multiple avenues for future growth.
• Key growth drivers to watch:
  • Successful launch and adoption of the longevity product line.
  • Rollout and performance of Hormone Replacement Therapy (HRT).
  • Progress and revenue contribution from the expansion into Canada.
• While the company's growth is impressive, the fact that it is now driven more by higher spending per user than by new user acquisition suggests the business is maturing.
• The lack of a guidance increase is a key point to monitor in future quarters, as it could indicate a slowing growth rate.

Novo Nordisk (NVO)

• Novo Nordisk was mentioned not as an investment opportunity, but as a source of a significant risk factor for HIMS.
• Novo Nordisk announced it would no longer partner with telehealth companies (like HIMS) for prescribing its popular GLP-1 drugs (like Ozempic).
• This decision created an "earthquake" for HIMS, likely causing a loss of sales and reducing the effectiveness of its marketing spend in the latter part of the quarter.

Takeaways

• For investors in HIMS, actions by major pharmaceutical companies like Novo Nordisk represent an external risk.
• This event highlights the dependency HIMS and other telehealth platforms can have on partnerships with drug manufacturers.
• HIMS's strategy to pivot and build its business "beyond just weight loss" (e.g., into longevity and HRT) is a direct response to mitigate this type of risk.